thiazoles has been researched along with Arteriosclerosis in 70 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 16 (22.86) | 18.2507 |
| 2000's | 53 (75.71) | 29.6817 |
| 2010's | 1 (1.43) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Arsiwala, T; Auwerx, J; Ellis, JL; Gomes, AP; Hottiger, MO; Lohmann, C; Lüscher, TF; Lutz, TA; Matter, CM; Miranda, MX; Schoonjans, K; Sinclair, DA; Staels, B; Stein, S; Suri, V; Tailleux, A; van Tits, LJ; Winnik, S | 1 |
| Hirata, Y; Isobe, M; Nagai, R; Ogawa, M; Suzuki, J | 1 |
| Aljada, A; Dandona, P | 1 |
| Sugiyama, Y | 1 |
| Kawakami, M; Kuroki, M | 1 |
| Egashira, K; Hiasa, K; Ichiki, T; Inoue, S; Ishibashi, M; Kitamoto, S; Ni, W; Takeshita, A; Usui, M; Zhao, Q | 1 |
| Asnani, S; Fonseca, VA; Gouda, BP | 1 |
| Cohen, H; Dvir, A; Gerber, Y; Harats, D; Levi, Z; Levkovitz, H; Ravid, M; Rhachmani, R; Shaish, A; Trestman, S; Yacov, N | 1 |
| Yamada, N; Yatoh, S | 1 |
| Iida, KT; Iwama, Y; Kamata, K; Kawakami, Y; Mokuno, H; Shimada, K; Shimano, H; Sone, H; Suzuki, M; Toyoshima, H; Watanabe, Y; Yamada, N | 1 |
| Dandona, P | 2 |
| Viberti, GC | 1 |
| Tafuri, S; Wang, M | 1 |
| Bernal, MR; Calle-Pascual, AL; Fernández-Cruz, A; Goldfine, A; Horton, E; Jarolim, P; Libby, P; Nuzzo, R; Schönbeck, U; Varo, JJ; Varo, N; Veves, A; Vicent, D | 1 |
| Braunstein, S | 1 |
| Chatterjee, VK; Gurnell, M; O'Rahilly, S; Savage, DB | 1 |
| Cabré, A; Camejo, G; Hultén, LM; Norén, K; Pedreño, J; Svensson, L; Vallvé, JC; Wiklund, O | 1 |
| Stumvoll, M | 1 |
| Echizen, H; Oishi, K; Uchida, M; Yamaguchi, T | 1 |
| Allen, TJ; Burns, WC; Candido, R; Cooper, ME; Deemer, EK; Forbes, JM; Jandeleit-Dahm, KA; Lassila, M; Thallas, V; Thomas, MC; Thorpe, SM; Thorpe, SR; Yee, LT | 1 |
| Cui, H; Li, S; Wang, LL; Zhong, W | 1 |
| Graham, TL; Mookherjee, C; Palmer, CN; Patel, L; Suckling, KE | 1 |
| Allen, TJ; Jandeleit-Dahm, KA; Lassila, M | 1 |
| Coats, W; Faxon, D; Graf, K; Hsueh, WA; Law, RE; Meehan, WP; Wuthrich, DA; Xi, XP | 1 |
| Campagnola, M; Cominacini, L; Davoli, A; Fratta Pasini, A; Garbin, U; Lo Cascio, V; Pastorino, AM; Rigoni, A | 1 |
| Aikawa, E; Demura, H; Demura, R; Imaki, T; Naruse, K; Naruse, M; Nishikawa, M; Seki, T; Tanabe, A; Yoshimoto, T | 1 |
| Campagnola, M; Cominacini, L; Davoli, A; Ferrannini, E; Foot, E; Fratta Pasini, A; Garbin, U; Lo Cascio, V; Sighieri, G; Sironi, AM | 1 |
| Aviram, M; Rosenblat, M | 1 |
| Frei, B; Gokce, N; Holbrook, M; Keaney, JF; Leaf, C; Vita, JA | 1 |
| Funahashi, T; Kihara, S; Matsuzawa, Y; Ouchi, N; Shinohara, E; Tamura, R; Yamashita, S | 1 |
| Alvarez, JG; Evans, RM; Nagy, L; Thomazy, VA; Tontonoz, P | 1 |
| Libby, P; Marx, N; Murphy, C; Plutzky, J; Sukhova, G | 1 |
| Antonucci, M; Chapman, J; Chinetti, G; Delerive, P; Fruchart, JC; Griglio, S; Majd, Z; Najib, J; Staels, B; Torra, IP | 1 |
| Fonseca, VA; Granberry, MC | 1 |
| Horikoshi, H; Ito, T; Shiomi, M; Tsujita, Y; Tsukada, T | 1 |
| Demura, H; Irie, K; Muraki, T; Naruse, K; Naruse, M; Shizume, H; Tago, K; Tanabe, A; Tanaka, M; Yoshimoto, T; Zardi, L | 1 |
| Hunabiki, A; Kasuga, M; Morita, S | 1 |
| Pasceri, V; Willerson, JT; Wu, HD; Yeh, ET | 1 |
| Nagy, L; Tontonoz, P | 1 |
| Kuzuya, H; Nakano, T; Yamada, K | 1 |
| Mitchell, JA; Pepper, JR; Stanford, SJ | 1 |
| Fujiwara, T; Hashimoto, T; Horikoshi, H | 1 |
| Kruszynska, YT; Olefsky, JM; Sobel, BE; Yu, JG | 1 |
| Brown, KK; Glass, CK; Li, AC; Palinski, W; Silvestre, MJ; Willson, TM | 1 |
| Boullier, A; Chang, MK; Glass, CK; Green, SR; Han, KH; Li, A; Quehenberger, O | 1 |
| Glass, CK | 1 |
| Collins, AR; Hsueh, WA; Jackson, S; Kintscher, U; Law, RE; Meehan, WP; Noh, G; Palinski, W; Wakino, S | 1 |
| Chen, Z; Gotoda, T; Harada, K; Iizuka, Y; Ishibashi, S; Kitamine, T; Nagai, R; Ohashi, K; Okazaki, H; Perrey, S; Shimano, H; Shionoiri, F; Tamura, Y; Yahagi, N; Yamada, N | 1 |
| Aljada, A; Assian, E; Dandona, P; Garg, R; Ghanim, H; Hamouda, W; Kumbkarni, Y; Mohanty, P | 1 |
| Medina, G; Puig, AJ; Sewter, C | 1 |
| Eriksson, U; Hansson, GK; Romert, A; Sirsjö, A; Törmä, H; Wuttge, DM | 1 |
| Itoh, H; Nakao, K | 1 |
| Auwerx, J; Debril, MB; Fajas, L | 1 |
| Koshiyama, H; Kuwamura, N; Minamikawa, J; Nakamura, Y; Shimono, D | 1 |
| Daida, H; Hoshi, S; Iwama, Y; Mokuno, H; Sawano, M; Shimada, K; Sunayama, S; Watanabe, Y; Yamaguchi, H | 1 |
| Glazer, NB; Miskin, B; Prince, MJ; Robertson, KE; Rosenblatt, S | 1 |
| Chun, TH; Doi, K; Fukunaga, Y; Hosoda, K; Inoue, M; Itoh, H; Kook, H; Masatsugu, K; Nakao, K; Saito, T; Sawada, N; Tanaka, T; Ueda, M; Yamashita, J | 1 |
| Ando, K; Chiba, Y; Fujita, T; Ogita, T | 1 |
| Hombach, V; Marx, N | 1 |
| Badimon, JJ; Crandall, JP; Fallon, JT; Fuster, V; Heflt, G; Herson, P; Lev, EI; Osende, JI; Rabito, P; Rauch, U; Rodriguez, OJ; Vidhun, R; Zaman, A | 1 |
| Hsueh, WA; Law, RE | 1 |
| Kanai, H; Kurabayashi, M; Kuro-o, M; Nabeshima, Y; Nagai, R; Nakamura, T; Saito, Y; Sumino, H; Takeda, S; Yamagishi, T | 1 |
| Castro Cabezas, M; Erkelens, DW; van Dijk, H | 1 |
| Marra, F; Pastacaldi, S | 1 |
| Grüb, M; Hombach, V; Kehrle, B; Koenig, W; Kohlhammer, K; Libby, P; Marx, N; Plutzky, J | 1 |
| Chikara, S; Fukuda, N; Hu, WY; Kanmatsuse, K; Kishioka, H; Nakayama, M; Teng, J | 1 |
| Alomar, Y; Levade, T; Nègre-Salvayre, A; Salvayre, R; Valdiguié, P | 1 |
26 review(s) available for thiazoles and Arteriosclerosis
| Article | Year |
|---|---|
A rational approach to pathogenesis and treatment of type 2 diabetes mellitus, insulin resistance, inflammation, and atherosclerosis.
Topics: Anti-Inflammatory Agents; Arteriosclerosis; Diabetes Mellitus, Type 2; Humans; Hypoglycemic Agents; Inflammation; Insulin; Insulin Resistance; Thiazoles | 2002 |
[Mechanisms of thiazolidinedione derivatives for hypoglycemic and insulin sensitizing effects].
Topics: Animals; Arteriosclerosis; Diabetes Mellitus; Diabetes Mellitus, Type 2; Humans; Hypoglycemic Agents; Insulin Resistance; Ligands; Lipid Metabolism; Obesity; Pioglitazone; Receptors, Cytoplasmic and Nuclear; Thiazoles; Thiazolidinediones; Transcription Factors | 2002 |
[Aminoguanidine and other AGE inhibitors].
Topics: Amides; Animals; Arteriosclerosis; Cardiovascular Diseases; Cataract; Clinical Trials as Topic; Diabetes Mellitus; Diabetic Nephropathies; Diabetic Retinopathy; Disease Models, Animal; Drug Design; Glycation End Products, Advanced; Guanidines; Humans; Hydrazines; Hypoglycemic Agents; Thiadiazoles; Thiazoles; Thiazolidines | 2002 |
Effects of thiazolidinediones on cardiovascular risk factors.
Topics: Arteriosclerosis; Cardiovascular Diseases; Diabetes Mellitus, Type 2; Fibrinolysis; Humans; Hyperlipidemias; Hypertension; Hypoglycemic Agents; Insulin Resistance; Risk Factors; Thiazoles; Vascular Resistance; Weight Gain | 2002 |
Insulin sensitizers and atherosclerosis.
Topics: Animals; Arteriosclerosis; Glucose Intolerance; Humans; Insulin; Insulin Resistance; Receptors, Cytoplasmic and Nuclear; Thiazoles; Transcription Factors | 2002 |
Insulin resistance and endothelial dysfunction in atherosclerosis: implications and interventions.
Topics: Arteriosclerosis; Cardiovascular Diseases; Endothelium, Vascular; Humans; Insulin Resistance; Receptors, Cytoplasmic and Nuclear; Thiazoles; Transcription Factors | 2002 |
Endothelium, inflammation, and diabetes.
Topics: Animals; Anti-Inflammatory Agents; Arteriosclerosis; Diabetes Complications; Diabetes Mellitus; Diabetic Angiopathies; Endothelium, Vascular; Glucose; Humans; Insulin; Oxidative Stress; Thiazoles; Thiazolidinediones; Vasculitis | 2002 |
Rosiglitazone: potential beneficial impact on cardiovascular disease.
Topics: Albuminuria; Arteriosclerosis; Diabetes Mellitus; Diabetes Mellitus, Type 2; Diabetic Angiopathies; Humans; Hyperglycemia; Hyperlipidemias; Hypertension; Hypoglycemic Agents; Insulin Resistance; Obesity; Risk Factors; Rosiglitazone; Thiazoles; Thiazolidinediones | 2003 |
Modulation of PPARgamma activity with pharmaceutical agents: treatment of insulin resistance and atherosclerosis.
Topics: Animals; Arteriosclerosis; Diabetes Mellitus, Type 2; Humans; Hypoglycemic Agents; Insulin Resistance; Models, Biological; Receptors, Cytoplasmic and Nuclear; Thiazoles; Thiazolidinediones; Transcription Factors | 2003 |
Cardiovascular disease and benefits of thiazolidinediones.
Topics: Arteriosclerosis; Blood Pressure; Blood Vessels; Cardiovascular Diseases; Humans; Hypercholesterolemia; Hypoglycemic Agents; Islets of Langerhans; Thiazoles; Thiazolidinediones | 2003 |
The metabolic syndrome: peroxisome proliferator-activated receptor gamma and its therapeutic modulation.
Topics: Adipose Tissue; Animals; Arteriosclerosis; Humans; Hyperlipidemias; Hypertension; Hypoglycemic Agents; Insulin Resistance; Metabolic Syndrome; Mutation; Receptors, Cytoplasmic and Nuclear; Thiazoles; Thiazolidinediones; Transcription Factors | 2003 |
Thiazolidinediones -- some recent developments.
Topics: Adipose Tissue; Animals; Anti-Inflammatory Agents, Non-Steroidal; Arteriosclerosis; Cyclic AMP-Dependent Protein Kinases; Diabetes Mellitus, Type 2; Humans; Hypoglycemic Agents; Insulin Resistance; Receptors, Cytoplasmic and Nuclear; Thiazoles; Transcription Factors | 2003 |
[Targeted AGEes and AGEs cross-link in drug discovery: preventing and reversing arterial sclerosis in aging and diabetes].
Topics: Aging; Animals; Arteries; Arteriosclerosis; Blood Pressure; Diabetes Mellitus; Glycation End Products, Advanced; Guanidines; Humans; Thiazoles | 2005 |
Advanced glycation end products in diabetes-associated atherosclerosis and renal disease: interventional studies.
Topics: Amides; Animals; Arteriosclerosis; Diabetic Angiopathies; Diabetic Nephropathies; Glycation End Products, Advanced; Humans; Hydrazines; Receptor for Advanced Glycation End Products; Receptors, Immunologic; Thiazoles | 2005 |
Insulin resistance syndrome: options for treatment.
Topics: Arteriosclerosis; Chromans; Diabetes Mellitus; Diabetes Mellitus, Type 2; Female; Humans; Hyperlipidemias; Hypertension; Hypoglycemic Agents; Insulin Resistance; Male; Metformin; Microvascular Angina; Obesity; Thiazoles; Thiazolidinediones; Troglitazone | 1999 |
[Etiology and therapy of insulin resistance].
Topics: Animals; Arteriosclerosis; Biguanides; Diabetes Mellitus, Type 2; Humans; Hyperlipidemias; Hypertension; Insulin Resistance; Life Style; Obesity; Risk Factors; Thiazoles; Thiazolidinediones; Tumor Necrosis Factor-alpha | 1999 |
Regulation of macrophage gene expression by peroxisome-proliferator-activated receptor gamma: implications for cardiovascular disease.
Topics: Animals; Arteriosclerosis; Cardiovascular Diseases; DNA-Binding Proteins; Fatty Acids; Gene Expression Regulation; Humans; Hypoglycemic Agents; Macrophages; Oxidation-Reduction; Receptors, Cytoplasmic and Nuclear; Signal Transduction; Thiazoles; Transcription Factors | 1999 |
[Cardiovascular effects of the thiazolidinedione troglitazone].
Topics: Animals; Arteriosclerosis; Cardiovascular Diseases; Cardiovascular System; Chromans; Diabetes Mellitus, Type 2; Humans; Hyperinsulinism; Hyperlipidemias; Hypertension; Hypoglycemic Agents; Insulin Resistance; Risk Factors; Syndrome; Thiazoles; Thiazolidinediones; Troglitazone | 2000 |
Troglitazone and emerging glitazones: new avenues for potential therapeutic benefits beyond glycemic control.
Topics: Animals; Arteriosclerosis; Blood Coagulation Disorders; Cardiac Output; Cholesterol; Chromans; Endothelium, Vascular; Fatty Acids, Nonesterified; Humans; Hypoglycemic Agents; Lipoproteins, LDL; Muscle, Smooth, Vascular; Thiazoles; Thiazolidinediones; Triglycerides; Troglitazone | 2000 |
[PPARgamma and thiazolidinediones, something more than a treatment for diabetes].
Topics: Arteriosclerosis; Cell Differentiation; Cell Transformation, Neoplastic; Diabetes Mellitus, Type 2; Female; Humans; Hypertension; Hypoglycemic Agents; Ligands; Male; Polycystic Ovary Syndrome; Protein Isoforms; Receptors, Cytoplasmic and Nuclear; Thiazoles; Thiazolidinediones; Transcription Factors | 2000 |
[Significance of PPAR gamma (peroxisome proliferator-activated receptor gamma) in atherosclerosis].
Topics: Animals; Arteriosclerosis; Cell Differentiation; Humans; Insulin Resistance; Ligands; Lipoproteins, LDL; Macrophages; Mice; Muscle, Smooth, Vascular; Rats; Receptors, Cytoplasmic and Nuclear; Thiazoles; Thiazolidinediones; Transcription Factors | 2001 |
PPAR gamma: an essential role in metabolic control.
Topics: Adipose Tissue; Animals; Arteriosclerosis; Gene Expression; Humans; Inflammation; Insulin; Ligands; Prostaglandin D2; Receptors, Cytoplasmic and Nuclear; Thiazoles; Thiazolidinediones; Transcription Factors | 2001 |
[Peroxisome proliferator-activated receptors (PPARs) in the vessel wall: new regulators of gene expression in vascular cells].
Topics: Animals; Arteriosclerosis; Chromans; Clinical Trials as Topic; Coronary Disease; Diabetes Mellitus, Type 2; Female; Fenofibrate; Gemfibrozil; Gene Expression Regulation; Humans; Hypoglycemic Agents; Hypolipidemic Agents; Inflammation; Ligands; Male; Mice; Muscle, Smooth, Vascular; Peroxisome Proliferators; Rats; Research; Thiazoles; Thiazolidinediones; Transcription Factors; Troglitazone | 2001 |
PPARgamma and atherosclerosis: effects on cell growth and movement.
Topics: Animals; Arteriosclerosis; Cell Division; Cell Movement; Endothelium, Vascular; Humans; Metabolic Syndrome; Muscle, Smooth, Vascular; Pioglitazone; Receptors, Cytoplasmic and Nuclear; Rosiglitazone; Thiazoles; Thiazolidinediones; Transcription Factors | 2001 |
[Free fatty acids: mediators of insulin resistance and atherosclerosis].
Topics: Arteriosclerosis; Complement C3; Fatty Acids, Nonesterified; Humans; Insulin Resistance; Lipoproteins; Receptors, Cytoplasmic and Nuclear; Thiazoles; Transcription Factors; Triglycerides | 2002 |
[Thiazolidinediones and PPARgamma system in repair of liver damage].
Topics: Anti-Inflammatory Agents, Non-Steroidal; Antineoplastic Agents; Antioxidants; Arteriosclerosis; Chromans; Diabetes Mellitus, Type 2; Eicosanoids; Fatty Acids; Forecasting; Humans; Hypoglycemic Agents; In Vitro Techniques; Inflammation; Liver Cirrhosis; Neoplasms; Obesity; Receptors, Cytoplasmic and Nuclear; Research; Thiazoles; Thiazolidinediones; Transcription Factors; Troglitazone | 2002 |
6 trial(s) available for thiazoles and Arteriosclerosis
| Article | Year |
|---|---|
Elevated plasma levels of the atherogenic mediator soluble CD40 ligand in diabetic patients: a novel target of thiazolidinediones.
Topics: Acute Disease; Adult; Aged; Arteriosclerosis; Body Mass Index; CD40 Ligand; Chromans; Chronic Disease; Cross-Sectional Studies; Diabetes Mellitus, Type 1; Diabetes Mellitus, Type 2; Female; Humans; Hypoglycemic Agents; Longitudinal Studies; Male; Metformin; Pilot Projects; Receptors, Cytoplasmic and Nuclear; Reference Values; Risk Factors; Solubility; Spain; Thiazoles; Thiazolidinediones; Transcription Factors; Treatment Outcome; Troglitazone | 2003 |
Troglitazone reduces LDL oxidation and lowers plasma E-selectin concentration in NIDDM patients.
Topics: Analysis of Variance; Arteriosclerosis; Cholesterol, LDL; Chromans; Diabetes Mellitus, Type 2; Double-Blind Method; E-Selectin; Endothelium, Vascular; Female; Fluorescence; Humans; Hypoglycemic Agents; Male; Middle Aged; Oxidation-Reduction; Peroxides; Thiazoles; Thiazolidinediones; Thiobarbituric Acid Reactive Substances; Troglitazone; Vitamin E | 1998 |
L-2-Oxothiazolidine-4-carboxylic acid reverses endothelial dysfunction in patients with coronary artery disease.
Topics: Administration, Oral; Aged; Arteriosclerosis; Blood Flow Velocity; Blood Glucose; Blood Pressure; Cholesterol; Coronary Disease; Cysteine; Double-Blind Method; Endothelium, Vascular; Female; Glutathione; Heart Rate; Humans; Hyperemia; Male; Middle Aged; Nitric Oxide; Nitroglycerin; Oxidation-Reduction; Pyrrolidonecarboxylic Acid; Thiazoles; Thiazolidines; Triglycerides; Ultrasonography | 1998 |
Rapid communication: inhibitory effect of pioglitazone on carotid arterial wall thickness in type 2 diabetes.
Topics: Arteriosclerosis; Blood Pressure; Carotid Arteries; Diabetes Mellitus, Type 2; Female; Glycated Hemoglobin; Humans; Hypoglycemic Agents; Lipids; Male; Middle Aged; Pioglitazone; Thiazoles; Thiazolidinediones | 2001 |
The impact of pioglitazone on glycemic control and atherogenic dyslipidemia in patients with type 2 diabetes mellitus.
Topics: Adult; Aged; Arteriosclerosis; Blood Glucose; C-Peptide; Diabetes Mellitus, Type 2; Double-Blind Method; Endpoint Determination; Female; Follow-Up Studies; Glycated Hemoglobin; Humans; Hyperlipidemias; Hypoglycemic Agents; Insulin; Insulin Resistance; Islets of Langerhans; Lipids; Lipoproteins; Male; Middle Aged; Pioglitazone; Single-Blind Method; Thiazoles; Thiazolidinediones; Treatment Outcome; United States | 2001 |
Blood thrombogenicity in type 2 diabetes mellitus patients is associated with glycemic control.
Topics: Analysis of Variance; Arteriosclerosis; Blood Coagulation; Blood Coagulation Tests; Chromans; Combined Modality Therapy; Diabetes Mellitus, Type 2; Diet, Diabetic; Double-Blind Method; Female; Glycated Hemoglobin; Humans; Hypoglycemic Agents; Male; Middle Aged; Predictive Value of Tests; Thiazoles; Thiazolidinediones; Thrombosis; Troglitazone | 2001 |
38 other study(ies) available for thiazoles and Arteriosclerosis
| Article | Year |
|---|---|
The Sirt1 activator SRT3025 provides atheroprotection in Apoe-/- mice by reducing hepatic Pcsk9 secretion and enhancing Ldlr expression.
Topics: Anilides; Animals; Anticholesteremic Agents; Apolipoproteins E; Arteriosclerosis; Cells, Cultured; Cholesterol, LDL; Enzyme Inhibitors; Hepatocytes; In Vitro Techniques; Male; Mice, Inbred C57BL; Proprotein Convertase 9; Proprotein Convertases; Receptors, LDL; RNA, Messenger; Serine Endopeptidases; Sirtuin 1; Thiazoles | 2015 |
A critical role of COX-2 in the progression of neointimal formation after wire injury in mice.
Topics: Animals; Arteriosclerosis; Cell Line; Cyclooxygenase 2; Cyclooxygenase 2 Inhibitors; Disease Progression; Endothelium, Vascular; Enzyme Induction; Femoral Artery; Interleukin-6; Macrophages; Male; Meloxicam; Mice; Mice, Inbred C57BL; RNA, Messenger; Stress, Mechanical; Thiazines; Thiazoles; Tunica Intima | 2009 |
[Prevention of arteriosclerosis with the insulin sensitizer pioglitazone. Early intervention in diabetic patients compensates "cell ignorance"].
Topics: Arteriosclerosis; Clinical Trials as Topic; Diabetes Mellitus, Type 2; Diabetic Angiopathies; Humans; Hypoglycemic Agents; Insulin Resistance; Pioglitazone; Thiazoles; Thiazolidinediones | 2002 |
[Early effect of therapy with pioglitazone. Vascular damage significantly reduced].
Topics: Arteriosclerosis; Carotid Stenosis; Clinical Trials as Topic; Diabetes Mellitus, Type 2; Diabetic Angiopathies; Humans; Hypoglycemic Agents; Pioglitazone; Thiazoles; Thiazolidinediones; Treatment Outcome | 2002 |
Antiinflammatory and antiarteriosclerotic effects of pioglitazone.
Topics: Animals; Anti-Inflammatory Agents; Arteriosclerosis; Blood Glucose; Blood Pressure; Chemokine CCL2; Coronary Artery Disease; Disease Models, Animal; Drug Evaluation, Preclinical; Inflammation; Insulin; Lipids; Male; Monocytes; Myocardium; NG-Nitroarginine Methyl Ester; Nitric Oxide Synthase; Nitric Oxide Synthase Type III; Peptidyl-Dipeptidase A; Pioglitazone; Rats; Rats, Inbred WKY; Receptors, CCR2; Receptors, Chemokine; Receptors, Cytoplasmic and Nuclear; RNA, Messenger; Thiazoles; Thiazolidinediones; Transcription Factors; Transforming Growth Factor beta; Transforming Growth Factor beta1; Treatment Outcome | 2002 |
Rosiglitazone (PPARgamma-agonist) attenuates atherogenesis with no effect on hyperglycaemia in a combined diabetes-atherosclerosis mouse model.
Topics: Animals; Aortic Diseases; Apolipoproteins E; Arteriosclerosis; Blood Glucose; Cholesterol; Diabetes Mellitus, Experimental; Diabetic Angiopathies; Fibrinolytic Agents; Male; Mice; Receptors, Cytoplasmic and Nuclear; Rosiglitazone; Thiazoles; Thiazolidinediones; Transcription Factors; Triglycerides | 2003 |
Effect of thiazolidinediones and metformin on LDL oxidation and aortic endothelium relaxation in diabetic GK rats.
Topics: Acetylcholine; Animals; Aorta, Thoracic; Arteriosclerosis; Cholesterol, LDL; Chromans; Diabetes Mellitus, Type 2; Endothelium, Vascular; Hypoglycemic Agents; Isometric Contraction; Lipid Peroxidation; Lipids; Male; Metformin; Muscle Contraction; Muscle Relaxation; Oxidation-Reduction; Pioglitazone; Rats; Rats, Wistar; Thiazoles; Thiazolidinediones; Troglitazone; Vasodilator Agents | 2003 |
Fatty acids modulate the effect of darglitazone on macrophage CD36 expression.
Topics: Arteriosclerosis; CD36 Antigens; Diabetes Mellitus, Type 2; Fatty Acids; Humans; Macrophages; Receptors, Immunologic; Receptors, Scavenger; Reverse Transcriptase Polymerase Chain Reaction; RNA, Messenger; Thiazoles; Thiazolidinediones | 2003 |
Edaravone, a radical scavenger, may enhance or produce antiproliferative effects of fluvastatin, amlodipine, ozagrel, GF109203X and Y27632 on cultured basilar artery smooth muscle cells.
Topics: Amides; Amlodipine; Animals; Antipyrine; Arteriosclerosis; Basilar Artery; Cell Division; Cell Survival; Cells, Cultured; Drug Synergism; Drug Therapy, Combination; Edaravone; Enzyme Inhibitors; Fatty Acids, Monounsaturated; Fluvastatin; Free Radical Scavengers; Indoles; Maleimides; Methacrylates; Muscle, Smooth, Vascular; Pyridines; Reactive Oxygen Species; Signal Transduction; Tetrazolium Salts; Thiazoles | 2003 |
Advanced glycation end product interventions reduce diabetes-accelerated atherosclerosis.
Topics: Actins; Animals; Aorta; Arteriosclerosis; Collagen; Cytokines; Diabetes Mellitus, Experimental; Diabetic Angiopathies; Glycation End Products, Advanced; Guanidines; Lipid Metabolism; Male; Mice; Mice, Inbred C57BL; Mice, Knockout; Muscle, Smooth; Oxidation-Reduction; Skin; Thiazoles | 2004 |
The PPARdelta agonist GW0742X reduces atherosclerosis in LDLR(-/-) mice.
Topics: Animals; Aorta; Arteriosclerosis; Biomarkers; Body Weight; Eating; Inflammation; Lipids; Lipoproteins; Macrophages; Mice; Mice, Knockout; PPAR delta; Receptors, LDL; Thiazoles | 2005 |
Troglitazone inhibits vascular smooth muscle cell growth and intimal hyperplasia.
Topics: Animals; Arteriosclerosis; Calcium-Calmodulin-Dependent Protein Kinases; Cell Division; Cell Movement; Cells, Cultured; Chromans; DNA; Fibroblast Growth Factor 2; Genes, fos; Hyperplasia; Hypoglycemic Agents; Male; Muscle, Smooth, Vascular; Platelet-Derived Growth Factor; Rats; Rats, Sprague-Dawley; Thiazoles; Thiazolidinediones; Troglitazone | 1996 |
Effects of troglitazone on in vitro oxidation of LDL and HDL induced by copper ions and endothelial cells.
Topics: Arteriosclerosis; Cells, Cultured; Chromans; Copper; Diabetes Mellitus; Endothelium; Humans; Hypoglycemic Agents; Lipoproteins, HDL; Lipoproteins, LDL; Oxidation-Reduction; Thiazoles; Thiazolidinediones; Troglitazone; Vitamin E | 1997 |
Antihypertensive and vasculo- and renoprotective effects of pioglitazone in genetically obese diabetic rats.
Topics: Animals; Aorta; Arteriosclerosis; Blood Glucose; Blood Pressure; Cholesterol; Diabetes Mellitus; Diabetes Mellitus, Type 2; Diabetic Angiopathies; Diabetic Nephropathies; Epinephrine; Hypertension; Hypoglycemic Agents; Kidney Cortex; Kidney Glomerulus; Male; Norepinephrine; Obesity; Pioglitazone; Proteinuria; Rats; Rats, Inbred WF; Rats, Mutant Strains; Rats, Wistar; Sodium; Thiazoles; Thiazolidinediones; Triglycerides; Tunica Media | 1997 |
Macrophage glutathione content and glutathione peroxidase activity are inversely related to cell-mediated oxidation of LDL: in vitro and in vivo studies.
Topics: Animals; Apolipoproteins E; Arteriosclerosis; Buthionine Sulfoximine; Cell Line; Glutathione; Glutathione Peroxidase; Lipoproteins, LDL; Macrophages; Macrophages, Peritoneal; Mice; Mice, Transgenic; Oxidation-Reduction; Peroxides; Pyrrolidonecarboxylic Acid; Selenium; Superoxides; Thiazoles; Thiazolidines | 1998 |
Troglitazone enhances glucose uptake and inhibits mitogen-activated protein kinase in human aortic smooth muscle cells.
Topics: Aorta; Arteriosclerosis; Calcium-Calmodulin-Dependent Protein Kinases; Cell Division; Cells, Cultured; Chromans; DNA Replication; Glucose; Humans; Hypoglycemic Agents; Insulin; Insulin Resistance; Muscle, Smooth, Vascular; Thiazoles; Thiazolidinediones; Troglitazone | 1998 |
PPARgamma promotes monocyte/macrophage differentiation and uptake of oxidized LDL.
Topics: Alitretinoin; Animals; Arteriosclerosis; CD36 Antigens; Cell Differentiation; Dimerization; Foam Cells; HL-60 Cells; Humans; Ligands; Lipoproteins, LDL; Macrophages; Membrane Proteins; Mice; Mice, Transgenic; Monocytes; Promoter Regions, Genetic; Prostaglandin D2; Receptors, Cytoplasmic and Nuclear; Receptors, Immunologic; Receptors, Lipoprotein; Receptors, Retinoic Acid; Receptors, Scavenger; Retinoid X Receptors; Rosiglitazone; Scavenger Receptors, Class B; Signal Transduction; Thiazoles; Thiazolidinediones; Transcription Factors; Transcriptional Activation; Tretinoin | 1998 |
Macrophages in human atheroma contain PPARgamma: differentiation-dependent peroxisomal proliferator-activated receptor gamma(PPARgamma) expression and reduction of MMP-9 activity through PPARgamma activation in mononuclear phagocytes in vitro.
Topics: Arteriosclerosis; Blotting, Northern; Blotting, Western; Cell Line; Cells, Cultured; Chromans; Collagenases; Humans; Immunoenzyme Techniques; Macrophages; Matrix Metalloproteinase 9; Monocytes; Prostaglandin D2; Receptors, Cytoplasmic and Nuclear; RNA, Messenger; Tetradecanoylphorbol Acetate; Thiazoles; Thiazolidinediones; Transcription Factors; Troglitazone | 1998 |
Activation of proliferator-activated receptors alpha and gamma induces apoptosis of human monocyte-derived macrophages.
Topics: Apoptosis; Arteriosclerosis; Caspase 3; Caspases; Cell Differentiation; Humans; Immunohistochemistry; Inflammation; Interferon-gamma; Ligands; Macrophages; NF-kappa B; Pyrimidines; Receptors, Cytoplasmic and Nuclear; RNA, Messenger; Rosiglitazone; Signal Transduction; Thiazoles; Thiazolidinediones; Transcription Factors; Transcription, Genetic; Transfection; Tumor Necrosis Factor-alpha | 1998 |
Combination treatment with troglitazone, an insulin action enhancer, and pravastatin, an inhibitor of HMG-CoA reductase, shows a synergistic effect on atherosclerosis of WHHL rabbits.
Topics: Animals; Aorta, Thoracic; Arteriosclerosis; Blood Glucose; Cholesterol, LDL; Chromans; Coronary Vessels; Disease Models, Animal; Drug Synergism; Drug Therapy, Combination; Female; Glucose Tolerance Test; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hyperinsulinism; Hyperlipoproteinemia Type II; Hypoglycemic Agents; Insulin Resistance; Male; Pravastatin; Rabbits; Thiazoles; Thiazolidinediones; Troglitazone; Xanthomatosis | 1999 |
Vasculo-protective effects of insulin sensitizing agent pioglitazone in neointimal thickening and hypertensive vascular hypertrophy.
Topics: Animals; Aorta, Abdominal; Arteriosclerosis; Bromodeoxyuridine; Carotid Arteries; Cell Division; DNA; Fibronectins; Hypertension; Hypertrophy; Hypoglycemic Agents; Male; Mesenteric Arteries; Muscle, Smooth, Vascular; Pioglitazone; Random Allocation; Rats; Rats, Inbred SHR; Rats, Inbred WKY; Thiazoles; Thiazolidinediones; Tunica Intima | 1999 |
Modulation of vascular inflammation in vitro and in vivo by peroxisome proliferator-activated receptor-gamma activators.
Topics: Animals; Arteriosclerosis; Cell Movement; Cells, Cultured; Chromans; Endothelium, Vascular; Humans; Intercellular Adhesion Molecule-1; Macrophages; Mice; Monocytes; Platelet Endothelial Cell Adhesion Molecule-1; Receptors, Cytoplasmic and Nuclear; Thiazoles; Thiazolidinediones; Transcription Factors; Troglitazone; Vascular Cell Adhesion Molecule-1; Vasculitis | 2000 |
Cyclooxygenase-2 regulates granulocyte-macrophage colony-stimulating factor, but not interleukin-8, production by human vascular cells: role of cAMP.
Topics: Anti-Inflammatory Agents, Non-Steroidal; Antineoplastic Agents; Arteriosclerosis; Aspirin; Bucladesine; Cells, Cultured; Cyclic AMP; Cyclooxygenase 2; Cyclooxygenase 2 Inhibitors; Cyclooxygenase Inhibitors; Dinoprostone; Epoprostenol; Granulocyte-Macrophage Colony-Stimulating Factor; Humans; Indans; Indomethacin; Interleukin-1; Interleukin-8; Isoenzymes; Mammary Arteries; Meloxicam; Membrane Proteins; Muscle, Smooth, Vascular; Neutrophils; Prostaglandin-Endoperoxide Synthases; Saphenous Vein; Sulfonamides; Thiazines; Thiazoles; Tumor Necrosis Factor-alpha | 2000 |
Effects of troglitazone on blood concentrations of plasminogen activator inhibitor 1 in patients with type 2 diabetes and in lean and obese normal subjects.
Topics: Adult; Arteriosclerosis; Blood Glucose; Chromans; Diabetes Mellitus, Type 2; Female; Fibrinolysis; Glucose Clamp Technique; Humans; Hyperinsulinism; Hypoglycemic Agents; Insulin; Insulin Resistance; Male; Middle Aged; Obesity; Plasminogen Activator Inhibitor 1; Thiazoles; Thiazolidinediones; Tissue Plasminogen Activator; Troglitazone | 2000 |
Peroxisome proliferator-activated receptor gamma ligands inhibit development of atherosclerosis in LDL receptor-deficient mice.
Topics: Animals; Arteriosclerosis; Base Sequence; CD36 Antigens; DNA Primers; Female; Gene Expression; Humans; Insulin Resistance; Ligands; Male; Matrix Metalloproteinase 9; Membrane Proteins; Mice; Mice, Inbred C57BL; Mice, Knockout; Oxazoles; Receptors, Cytoplasmic and Nuclear; Receptors, Immunologic; Receptors, LDL; Receptors, Lipoprotein; Receptors, Scavenger; RNA, Messenger; Rosiglitazone; Scavenger Receptors, Class B; Thiazoles; Thiazolidinediones; Transcription Factors; Tumor Necrosis Factor-alpha; Tyrosine | 2000 |
Oxidized LDL reduces monocyte CCR2 expression through pathways involving peroxisome proliferator-activated receptor gamma.
Topics: Animals; Apolipoproteins B; Arteriosclerosis; Cells, Cultured; Down-Regulation; Humans; Linoleic Acid; Linoleic Acids; Linoleic Acids, Conjugated; Lipoproteins, LDL; Mice; Monocytes; Muscle, Smooth, Vascular; Phospholipids; Receptors, CCR2; Receptors, Chemokine; Receptors, Cytoplasmic and Nuclear; RNA, Messenger; Rosiglitazone; Signal Transduction; Thiazoles; Thiazolidinediones; Transcription Factors | 2000 |
Antiatherogenic effects of thiazolidinediones?
Topics: Animals; Arteriosclerosis; Cell Movement; Chromans; Diabetes Mellitus, Type 2; Dietary Fats; Humans; Monocytes; Receptors, LDL; Thiazoles; Thiazolidinediones; Troglitazone; Vasodilator Agents | 2001 |
Troglitazone inhibits formation of early atherosclerotic lesions in diabetic and nondiabetic low density lipoprotein receptor-deficient mice.
Topics: Animals; Antigens, CD; Antigens, Differentiation, Myelomonocytic; Aorta; Arteriosclerosis; Blood Glucose; Body Weight; Cell Movement; Cells, Cultured; Chemokine CCL2; Chromans; Diabetes Mellitus, Type 2; Dietary Carbohydrates; Dietary Fats; Endothelium, Vascular; Flavonoids; Fructose; Humans; Insulin; Lipids; Macrophages; Male; Mice; Mice, Inbred C57BL; Mice, Knockout; Monocytes; Receptors, LDL; Rosiglitazone; Thiazoles; Thiazolidinediones; Troglitazone; Tumor Cells, Cultured; Vasodilator Agents | 2001 |
Troglitazone inhibits atherosclerosis in apolipoprotein E-knockout mice: pleiotropic effects on CD36 expression and HDL.
Topics: Animals; Aorta; Apolipoproteins E; Arteriosclerosis; Blood Glucose; Blotting, Northern; Body Weight; CD36 Antigens; Cells, Cultured; Chromans; Fatty Acids, Nonesterified; Female; Gene Expression Regulation; Hypoglycemic Agents; Insulin; Lipids; Lipoprotein Lipase; Lipoproteins; Lipoproteins, HDL; Macrophages, Peritoneal; Male; Mice; Mice, Inbred C57BL; Mice, Knockout; Receptors, Cytoplasmic and Nuclear; RNA, Messenger; Thiazoles; Thiazolidinediones; Time Factors; Transcription Factors; Troglitazone | 2001 |
Suppression of nuclear factor-kappaB and stimulation of inhibitor kappaB by troglitazone: evidence for an anti-inflammatory effect and a potential antiatherosclerotic effect in the obese.
Topics: Adult; Anti-Inflammatory Agents; Arteriosclerosis; Blood Glucose; C-Reactive Protein; Cell Nucleus; Chemokine CCL2; Chromans; Female; Humans; I-kappa B Proteins; Insulin; Intercellular Adhesion Molecule-1; Interleukin-10; Leukocytes, Mononuclear; Male; Middle Aged; NADPH Oxidases; NF-kappa B; Obesity; Phosphoproteins; Plasminogen Activator Inhibitor 1; Reactive Oxygen Species; Thiazoles; Thiazolidinediones; Troglitazone; Tumor Necrosis Factor-alpha | 2001 |
Induction of CD36 by all-trans retinoic acid: retinoic acid receptor signaling in the pathogenesis of atherosclerosis.
Topics: Arteriosclerosis; CD36 Antigens; Cell Line; Cells, Cultured; Fibrinolytic Agents; Gene Expression Regulation; Humans; Lipoproteins, LDL; Monocytes; Muscle, Smooth, Vascular; Receptors, Cytoplasmic and Nuclear; Receptors, Retinoic Acid; Reverse Transcriptase Polymerase Chain Reaction; Rosiglitazone; Signal Transduction; Thiazoles; Thiazolidinediones; Transcription Factors; Tretinoin | 2001 |
Troglitazone improves endothelial dysfunction in patients with insulin resistance.
Topics: Adult; Arteriosclerosis; Brachial Artery; Case-Control Studies; Chromans; Endothelium, Vascular; Glucose Tolerance Test; Humans; Hypoglycemic Agents; Insulin; Insulin Resistance; Male; Middle Aged; Thiazoles; Thiazolidinediones; Troglitazone; Vasodilation | 2000 |
Thiazolidinediones, peroxisome proliferator-activated receptor gamma agonists, regulate endothelial cell growth and secretion of vasoactive peptides.
Topics: Animals; Arteriosclerosis; Carotid Arteries; Cattle; Cell Division; Cells, Cultured; Chromans; Coronary Vessels; Dose-Response Relationship, Drug; Endothelins; Endothelium, Vascular; Gene Expression; Humans; Hypoglycemic Agents; Natriuretic Peptide, C-Type; Pioglitazone; Radioimmunoassay; Receptors, Cytoplasmic and Nuclear; Thiazoles; Thiazolidinediones; Transcription Factors; Troglitazone; Vasodilator Agents; Vasomotor System | 2001 |
PPARgamma ligands inhibit TNF-alpha-induced LOX-1 expression in cultured endothelial cells.
Topics: Animals; Arteriosclerosis; Cattle; Cells, Cultured; Chromans; Drug Antagonism; Endothelium; Immunohistochemistry; Pioglitazone; Prostaglandin D2; Receptors, Cytoplasmic and Nuclear; Receptors, LDL; Receptors, Oxidized LDL; RNA, Messenger; Tetradecanoylphorbol Acetate; Thiazoles; Thiazolidinediones; Transcription Factors; Transcriptional Activation; Troglitazone; Tumor Necrosis Factor-alpha | 2001 |
Troglitazone improves endothelial function and augments renal klotho mRNA expression in Otsuka Long-Evans Tokushima Fatty (OLETF) rats with multiple atherogenic risk factors.
Topics: Animals; Arteriosclerosis; Chromans; Endothelium, Vascular; Glucuronidase; Hypertension; Kidney; Klotho Proteins; Male; Membrane Proteins; Metabolic Diseases; Obesity; Rats; Rats, Inbred OLETF; Risk Factors; RNA, Messenger; Thiazoles; Thiazolidinediones; Troglitazone; Vasodilator Agents | 2001 |
PPAR activators as antiinflammatory mediators in human T lymphocytes: implications for atherosclerosis and transplantation-associated arteriosclerosis.
Topics: Anti-Inflammatory Agents; Arteriosclerosis; CD4-Positive T-Lymphocytes; Cells, Cultured; Fenofibrate; Graft Survival; Heart Transplantation; Humans; Interferon-gamma; Interleukin-2; Lymphocyte Activation; Peroxisome Proliferators; Pioglitazone; Pyrimidines; Receptors, Cytoplasmic and Nuclear; Rosiglitazone; Thiazoles; Thiazolidinediones; Transcription Factors; Tumor Necrosis Factor-alpha | 2002 |
Troglitazone inhibits growth and improves insulin signaling by suppression of angiotensin II action in vascular smooth muscle cells from spontaneously hypertensive rats.
Topics: Angiotensin II; Animals; Arteriosclerosis; Cell Division; Cells, Cultured; Chromans; Depression, Chemical; DNA; Growth Substances; Insulin Receptor Substrate Proteins; Insulin Resistance; Male; Muscle, Smooth, Vascular; Phosphatidylinositol 3-Kinases; Phosphoproteins; Phosphorylation; Rats; Rats, Inbred SHR; Rats, Inbred WKY; Signal Transduction; Thiazoles; Thiazolidinediones; Troglitazone; Tyrosine | 2002 |
Oxidized HDL are much less cytotoxic to lymphoblastoid cells than oxidized LDL.
Topics: Arteriosclerosis; Cell Line; Copper; Copper Sulfate; Fatty Acids, Unsaturated; Humans; L-Lactate Dehydrogenase; Lipoproteins, HDL; Lipoproteins, LDL; Oxidation-Reduction; Tetrazolium Salts; Thiazoles; Thiobarbituric Acid Reactive Substances; Trypan Blue; Ultraviolet Rays | 1992 |